Efficacy of Majoon e Najah capsules in menopausal symptoms.

Assessing the efficacy of Majoon e Najah capsules (MNcf) in alleviating climacteric symptoms: A pilot study. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080737

Enrollment

Registered

2025-02-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N951- Menopausal and female climactericstates

Interventions

Intervention1: Majoon e Najah Capsules (MNcf): Capsule MNcf 500mg x 2 thrice a day (3gm) x 1 month Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: The patients for the study will be selected from the following criteria: 1. Females in the menopause age (45-55 years). 2. Subjects presenting with menopause related symptoms. 3. Subjects willing to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Female patients with treatment history of Diabetes mellitus, Malignancy etc.

Design outcomes

Primary

Measure	Time frame
Changes in Green Climacteric Scale.Timepoint: 1 month	—

Secondary

Measure	Time frame
Improvement in Vasomotor symptoms (hot flushes, sweating at night)Timepoint: 1 month	—

Countries

India

Contacts

Public ContactDr Abiha Ahmad Khan

Ajmal Khan Tibbiya College AMU Aligarh

abihaahmad89@gmail.com9620551870

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026